Randomized 87 patients to date in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED) ---- Continuing enrollment ...

MELVILLE, N.Y., March 27, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative”, "BRTX” or the "Company”) ...

Previously, the Company was licensed by the NYSDOH to act as a tissue bank for the processing of mesenchymal stem cells derived from ... is a cell-based secretome containing exosomes, proteins ...

In this study, we showed that the secretome of mesenchymal stem cells (MSCs), a complex mixture of growth factors, cytokines, extracellular vesicles, and other cell-secreted molecules with therapeutic ...

Stem cells such as mesenchymal stem cells (MSCs ... Various approaches are currently being employed to drive the MSC secretome toward a more anti-inflammatory and regenerative phenotype (88). Because ...

Human extracellular matrices can be edited in their composition using the CRISPR/Cas9 system, leading to materials exhibiting tailored regenerative capacities.